REPRIEVE A5332 Women's Ancillary Study

The Women’s objectives will answer questions on sex-specific mechanisms of cardiovascular disease risk and risk reduction within the context of A5332. In order for these questions to be addressed, a modest amount of additional blood will be collected during select A5332 visits in which blood is already being drawn (entry, year 1), as per the A5332 LPC. Additional funds are being offered to cover costs related to drawing this additional blood, as well as to further support participant remuneration (further support of participant remuneration is at the discretion of individual sites/local IRB’s). As discussed on REPRIEVE site calls and CROI/ACTG meetings and as delineated in protocol version 3.0, Women’s Objectives have been fully integrated into the REPRIEVE Trial (A5332).